| 1 |
34738628 | Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. | 2022 Jan |
2 |
| 2 |
34820006 | Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2022 Jan |
2 |
| 3 |
34822800 | Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α. | 2022 Jan 1 |
1 |
| 4 |
35120552 | GnRH antagonist weakens endometrial stromal cells growth ability by decreasing c-kit receptor expression. | 2022 Feb 4 |
1 |
| 5 |
35183792 | The synergistic therapeutic effect of Imatinib and Protein Kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors. | 2022 Feb 17 |
1 |
| 6 |
33289342 | Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins. | 2021 Mar |
1 |
| 7 |
33910311 | [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells]. | 2021 Mar 14 |
1 |
| 8 |
34087223 | Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. | 2021 Sep 5 |
1 |
| 9 |
34667163 | BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors. | 2021 Oct 19 |
1 |
| 10 |
34843676 | Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. | 2021 Dec 15 |
2 |
| 11 |
34938656 | Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways. | 2021 |
1 |
| 12 |
31776458 | Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. | 2020 Feb |
1 |
| 13 |
32606967 | Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib. | 2020 |
2 |
| 14 |
33022360 | Imatinib exhibit synergistic pleiotropy in the prevention of colorectal cancer by suppressing proinflammatory, cell survival and angiogenic signaling. | 2020 Dec |
1 |
| 15 |
33040790 | Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. | 2020 Sep 30 |
4 |
| 16 |
31138788 | A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer. | 2019 May 28 |
1 |
| 17 |
31233186 | Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy. | 2019 Aug |
1 |
| 18 |
31493871 | TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway. | 2019 Nov 5 |
1 |
| 19 |
29423045 | Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. | 2018 Jan 9 |
1 |
| 20 |
29552859 | [Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R]. | 2018 Jan |
1 |
| 21 |
29623544 | SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling. | 2018 Nov |
5 |
| 22 |
30671399 | Anti-growth Effects of Imatinib and GNF5 via Regulation of Skp2 in Human Hepatocellular Carcinoma Cells. | 2018 Dec |
2 |
| 23 |
27370604 | Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. | 2017 Jan 1 |
1 |
| 24 |
27718039 | 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. | 2017 Feb |
2 |
| 25 |
27875938 | The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. | 2017 May |
3 |
| 26 |
28069548 | Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. | 2017 Apr 5 |
2 |
| 27 |
28103766 | Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. | 2017 May 1 |
1 |
| 28 |
28403213 | M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. | 2017 |
2 |
| 29 |
28442505 | Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib. | 2017 Aug 15 |
1 |
| 30 |
28612529 | [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph +ALL Cell Line]. | 2017 Mar |
1 |
| 31 |
28616912 | [The Roles of Glut5 in Imatinib Resistance in the Ph+ Acute Lymphoblastic Leukemia Cell]. | 2017 May |
2 |
| 32 |
28962554 | Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. | 2017 Sep 29 |
2 |
| 33 |
28986256 | MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro. | 2017 Dec 9 |
1 |
| 34 |
29029406 | Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL. | 2017 Sep 12 |
1 |
| 35 |
29046392 | Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. | 2017 Dec 6 |
1 |
| 36 |
26893362 | RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor. | 2016 Mar 22 |
1 |
| 37 |
26919095 | Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. | 2016 Apr 5 |
3 |
| 38 |
24706111 | microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. | 2015 May |
3 |
| 39 |
25182956 | KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. | 2015 Oct |
2 |
| 40 |
25757539 | PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). | 2015 Apr |
8 |
| 41 |
25889792 | The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. | 2015 Mar 24 |
2 |
| 42 |
25979368 | Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. | 2015 Aug |
3 |
| 43 |
26248946 | Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway. | 2015 Oct |
3 |
| 44 |
26473951 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. | 2015 |
1 |
| 45 |
24100660 | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. | 2014 Feb |
1 |
| 46 |
24699303 | Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. | 2014 Nov |
1 |
| 47 |
25151958 | AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells. | 2014 Dec |
1 |
| 48 |
23383209 | Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. | 2013 |
2 |
| 49 |
23462796 | Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. | 2013 Jun |
2 |
| 50 |
23749045 | Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. | 2013 Jun 7 |
1 |